Aileron shareholders approve 3M share increase for equity plan, authorize 100M common shares

Rein Therapeutics, Inc.

Stockholders approved conversion of Series X Convertible Preferred into common; pro forma shares outstanding ~29.5M.
Authorized common shares increased from 45M to 100M via certificate of amendment effective Feb 28, 2024.
2021 Stock Incentive Plan amended to add 3,000,000 shares; compensation vote advisory '1 Year' frequency adopted.
Three Class III directors elected (Alves-Aivado, Ambros, von Rickenbach) to three-year terms.
Anticipated automatic conversion of ~12,087 Series X shares into 12,087,075 common shares on March 5, 2024.

item 5.02 item 5.07 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Rein Therapeutics, Inc.: Increased authorized shares of common stock from 45,000,000 to 100,000,000 (effective 2024-02-28).

Change: charter amendment
Effective: 2024-02-28

Exact text from the filing

The Company filed the Certificate of Amendment to implement the increase in the number of authorized shares, which was effective upon filing, with the Secretary of State of the State of Delaware on February 28, 2024.

View on SEC.gov

Browse all governance changes →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-051759

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.